Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EVOQ Therapeutics
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
EVOQ Partners With Gilead On NanoDisc Approach To RA, Lupus
Michigan biotech follows 2021 collaboration in autoimmune disease with Amgen with its second tie-up, teaming up with Gilead in rheumatoid arthritis and systemic lupus erythematosus.
Adendra Launched To Unlock Immunotherapy Potential Of Dendritic Cells
Expertise in dendritic cells could help generate new targets in cancer and autoimmune disease immunotherapy.
Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
- Site Specific
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.